Chinese guideline for the laboratory diagnosis of venous thromboembolism (2026 edition)

Zhonghua Yi Xue Za Zhi. 2026 Oct 13;106(37):3956-3994. doi: 10.3760/cma.j.cn112137-20260507-01214.ABSTRACTVenous thromboembolism (VTE) is a multifactorial disease induced by the interplay between environmental exposures and genetic predisposition. It features intricate pathological mechanisms and an

E Expert Committee of the National Capacity Building Project for Pulmonary Embolism and Deep Venous Thrombosis Prevention and Treatment

Takayasu arteritis with giant coronary artery aneurysm: a case report

Zhonghua Nei Ke Za Zhi. 2026 Oct 1;65(10):1113-1115. doi: 10.3760/cma.j.cn112138-20260226-00106.ABSTRACT大动脉炎(TAK)是累及主动脉及其主要分支的慢性进展性、非特异性大血管炎。本文报道1例TAK伴右冠状动脉巨大动脉瘤(64 mm×41 mm)及瘤内血栓形成的病例,患者经甲泼尼龙抗炎、甲氨蝶呤联合阿达木单抗免疫抑制以及华法林抗凝等综合治疗后,病情得到控制。TAK累及冠状动脉并形成巨大动脉瘤较为罕见,且死亡风险高,本文旨在提高临床医师对该病的认识。.PMID:42855760 | DOI:10

Z Z H Wang

Gecacitinib as a bridging treatment to allogeneic hematopoietic stem cell transplantation for high-risk myelodysplastic syndrome with Behçet's syndrome: a case report

Zhonghua Nei Ke Za Zhi. 2026 Oct 1;65(10):1111-1112. doi: 10.3760/cma.j.cn112138-20260703-00410.ABSTRACT患者男,40岁,因发热伴全血细胞减少就诊,经骨髓形态学、病理及细胞/分子遗传学检查诊断为高危骨髓增生异常综合征(TP53突变、+8,合并骨髓纤维化),病程中出现腹痛、血便,肠镜及组织病理证实合并肠道白塞综合征,芦可替尼治疗无效。改用吉卡昔替尼(100 mg、2次/d)后骨髓原始细胞比例下降、肠道溃疡愈合,持续用药下成功桥接同胞全相合异基因造血干细胞移植,造血重建顺利,随访期间未发生移植物抗

W W Wu

Guidelines for the diagnosis and management of multiple myeloma in China (2026 revision)

Zhonghua Nei Ke Za Zhi. 2026 Oct 1;65(10):1041-1050. doi: 10.3760/cma.j.cn112138-20260803-00451.ABSTRACTMultiple myeloma (MM), an incurable malignancy characterized by the clonal proliferation of plasma cells, predominantly affects older adults and is the third most common hematologic malignancy in

C Chinese Medical Doctor Association, Hematology Branch

Treatment of relapsed/refractory multiple myeloma: new recommendations based on new evidence

Zhonghua Nei Ke Za Zhi. 2026 Oct 1;65(10):1038-1040. doi: 10.3760/cma.j.cn112138-20260806-00462.ABSTRACT随着新药的不断获批,复发难治性多发性骨髓瘤的治疗模式发生快速演变。《中国多发性骨髓瘤诊治指南(2026年修订)》基于目前国内获批骨髓瘤新药主要的临床研究结果,对复发难治性多发性骨髓瘤治疗推荐做了更新。本文主要对指南的核心观点及主要亮点进行解读。.PMID:42855749 | DOI:10.3760/cma.j.cn112138-20260806-00462

W W Gao